Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

DePuy Synthes Products Acquires 3D Printing Technology from TRS

Photonics.com
May 2017
WEST CHESTER, Pa., May 22, 2017 — Orthopaedics developer DePuy Synthes Products Inc., part of Johnson & Johnson, has acquired 3D printing technology from medical device company Tissue Regeneration Systems Inc. (TRS).

The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopaedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.

The acquisition from TRS brings new technology for personalized health care solutions in Trauma, a priority platform for the business. Johnson & Johnson aims to harness 3D printing technology to develop patient-specific health care solutions for increased satisfaction and better clinical outcomes.

"We are systematically investing in building a pipeline of 3D printed products," said Ciro Römer, company group chairman of DePuy Synthes. "The TRS technology, which will be added to the DePuy Synthes Trauma Platform, is the latest example of how we are working toward developing next-generation technologies that transform healthcare delivery with individualized solutions for patients."

DePuy Synthes began collaborating with TRS in 2014 through Johnson & Johnson Innovation, which seeks and invests in the best science and builds novel partnerships at all stages of development across the medical device, consumer healthcare and pharmaceutical sectors. Johnson & Johnson Innovation facilitated the collaboration between DePuy Synthes and TRS.

"The acquisition of the TRS technology by DePuy Synthes is testament to our ability to identify and work collaboratively with promising early-stage companies and entrepreneurs to accelerate bringing innovative new products to market," said Robert G. Urban, global head of Johnson & Johnson Innovation. "We are excited at the potential this technology holds to help improve patient outcomes."

TRS is an early-stage medical device company headquartered in Plymouth, Mich., that commercializes skeletal reconstruction and bone regeneration technology based on research performed at the University of Michigan and the University of Wisconsin. DePuy Synthes solutions focus on specialties such as joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, and are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.

BusinessDePuy Synthes ProductsTissue Regeneration SystemsJohnson & Johnson3d printingmaterialsacquisitionsAmericas

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.